Cited 0 times in
Hyperglycemia attenuates myocardial preconditioning of remifentanil
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽영란 | - |
dc.contributor.author | 김소연 | - |
dc.contributor.author | 심연희 | - |
dc.contributor.author | 황기철 | - |
dc.date.accessioned | 2014-12-19T17:16:38Z | - |
dc.date.available | 2014-12-19T17:16:38Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0022-4804 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91109 | - |
dc.description.abstract | BACKGROUND: Hyperglycemia attenuates cardioprotection by remifentanil-preconditioning in ischemia-reperfusion in vivo in diabetic rats. However, the effects of hyperglycemia in cultured ventricular myocytes remains unknown. Therefore, we examined the in vitro effects of hyperglycemia on hypoxia-reoxygenation (H/R) and cardioprotection from remifentanil-preconditioning in isolated neonatal rat ventricular myocytes (NRVMs), including effects on apoptotic signaling pathways and Ca(2+) homeostasis. MATERIALS AND METHODS: NRVMs were cultured in medium with 5.5 mM (normoglycemia) or 25.5 mM glucose for one day. Then, NRVMs in H/R groups were exposed to 1 h of hypoxia and 5 h of reoxygenation with or without remifentanil-preconditioning at 1 μM. Cell viability, apoptosis, and Ca(2+) homeostasis were assessed by MTT assay, caspase-3 assay, confocal microscopy and immunoblots. RESULTS: In normoglycemia, remifentanil-preconditioning improved the viability of cardiomyocytes (P < 0.01) and prevented the increase of caspase-3 activity and Ca(2+) overload after H/R injury (P < 0.05). In addition, decrease in Akt, ERK1/2, and Bcl-2, and the increase in Bax by H/R was attenuated by remifentanil-preconditioning (P < 0.05). However, in hyperglycemia, the viability was partially impaired after H/R but not improved by remifentanil-preconditioning. Apoptotic activity, Ca(2+) concentration, and apoptotic kinases except Akt were not affected by either H/R or remifentanil-preconditioning under hyperglycemia. Akt phosphorylation was decreased by H/R but not restored by remifentanil preconditioning. CONCLUSIONS: Remifentanil preconditioning under normoglycemia renders NRVMs resistant to H/R injury by reducing apoptosis and intracellular Ca(2+) concentrations. The mechanism appears to be modulation of apoptotic signaling. However, hyperglycemia mitigates H/R injury in NRVMs, and may reduce the protective effect of remifentanil-preconditioning that may be associated with the Akt pathways. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JOURNAL OF SURGICAL RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Analgesics, Opioid/pharmacology | - |
dc.subject.MESH | Analgesics, Opioid/therapeutic use* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Animals, Newborn | - |
dc.subject.MESH | Apoptosis/drug effects | - |
dc.subject.MESH | Calcium/metabolism | - |
dc.subject.MESH | Cell Survival/drug effects | - |
dc.subject.MESH | Cells, Cultured | - |
dc.subject.MESH | Extracellular Signal-Regulated MAP Kinases/metabolism | - |
dc.subject.MESH | Hyperglycemia/complications* | - |
dc.subject.MESH | Hyperglycemia/metabolism | - |
dc.subject.MESH | Hypoxia/complications* | - |
dc.subject.MESH | Hypoxia/drug therapy | - |
dc.subject.MESH | Hypoxia/metabolism | - |
dc.subject.MESH | Ischemic Preconditioning, Myocardial/methods* | - |
dc.subject.MESH | Myocytes, Cardiac/drug effects | - |
dc.subject.MESH | Myocytes, Cardiac/metabolism | - |
dc.subject.MESH | Piperidines/pharmacology | - |
dc.subject.MESH | Piperidines/therapeutic use* | - |
dc.subject.MESH | Proto-Oncogene Proteins c-akt/metabolism | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.title | Hyperglycemia attenuates myocardial preconditioning of remifentanil | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Anesthesiology (마취통증의학) | - |
dc.contributor.googleauthor | Hyun Soo Kim | - |
dc.contributor.googleauthor | So Yeon Kim | - |
dc.contributor.googleauthor | Young Lan Kwak | - |
dc.contributor.googleauthor | Ki Chul Hwang | - |
dc.contributor.googleauthor | Yon Hee Shim | - |
dc.identifier.doi | 21392805 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00172 | - |
dc.contributor.localId | A02196 | - |
dc.contributor.localId | A04456 | - |
dc.contributor.localId | A00616 | - |
dc.relation.journalcode | J01763 | - |
dc.identifier.eissn | 1095-8673 | - |
dc.identifier.pmid | 21392805 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0022480411000552 | - |
dc.subject.keyword | hyperglycemia | - |
dc.subject.keyword | hypoxia-reoxygenation injury | - |
dc.subject.keyword | remifentanil | - |
dc.subject.keyword | myocardial preconditioning | - |
dc.contributor.alternativeName | Kwak, Young Lan | - |
dc.contributor.alternativeName | Kim, So Yeon | - |
dc.contributor.alternativeName | Shim, Yon Hee | - |
dc.contributor.alternativeName | Hwang, Ki Chul | - |
dc.contributor.affiliatedAuthor | Kwak, Young Lan | - |
dc.contributor.affiliatedAuthor | Shim, Yon Hee | - |
dc.contributor.affiliatedAuthor | Hwang, Ki Chul | - |
dc.contributor.affiliatedAuthor | Kim, So Yeon | - |
dc.citation.volume | 174 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 231 | - |
dc.citation.endPage | 237 | - |
dc.identifier.bibliographicCitation | JOURNAL OF SURGICAL RESEARCH, Vol.174(2) : 231-237, 2012 | - |
dc.identifier.rimsid | 33923 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.